Key result
Stimulating cardiomyocyte proliferation or stem cell differentiation offers potential myocardial regeneration in end-stage HF.
Why the study?
Available therapeutic options are not applicable to all heart failure patients, driving interest in strategies to increase functioning cardiomyocytes via stimulation of cardiomyocyte proliferation or cardiac stem cell differentiation.
Stimulating endogenous cardiomyocyte proliferation represents a promising but early-stage therapeutic avenue for end-stage heart failure that requires careful control to avoid severe adverse effects like tumorigenesis.
Answers are grounded in this paper and cite their sources.
Not ready for clinical use in end-stage HF; leaves open whether controlled cardiomyocyte proliferation can achieve safe regeneration.
Heart failure (HF) is a clinical status defined as a final stage of many cardiac diseases featured by severely impaired systolic myocardial performance in a result of dramatic decline in a number of properly functioning cardiomyocytes. Currently, the available therapeutic options for HF patients are not applicable in all of them. Up to now, many strategies to increase a number of normal cardiomyocytes have been proposed. One of them, the most physiological one at glance, seems to be a stimulation of post-mitotic cardiomyocytes to proliferate/or cardiac stem cells to differentiate. In this review article, detailed background of such method of myocardial regeneration, including the physiological processes of cardiomyocyte transformation and maturation, is presented. Moreover, the latest directions of basic research devoted to develop sufficient and safe cardiomyocyte-based therapies of the end-stage HF individuals are discussed. Concluding, this direction of further research seems to be justified particularly in a view of human population aging, an increased prevalence of HF and higher expectations of improved efficiency of patients’ care.
No takes yet. Share an insight, caveat, or question.
Perek et al. (2021) conducted a review in Heart failure (HF). Stimulation of post-mitotic cardiomyocytes to proliferate or cardiac stem cells to differentiate was evaluated. Stimulation of post-mitotic cardiomyocytes to proliferate or cardiac stem cells to differentiate represents a potential physiological strategy for myocardial regeneration in end-stage heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: